🤖 GLOBAL HEALTH OPTIMIZATION AGENT v3.0

🔬 Current Disease Focus:

Task Progress: 0%

👥 Active Problem Solvers

🌍 Experts collaborating globally

⚡ Current Task Assignment

🧬 Genetic Analysis

🔄 Matching experts to specific tasks

📊 Resource Allocation by Research Phase:

📚 Data Analysis

🧪 Experimental Design

🔬 Clinical Trials

💊 Treatment Development

Trial Search

Current Search Criteria:

Intervention: GW642444 25mcg

Found 26 matching trials

Study to Assess the Safety and PK of GSK573719 and GSK573719/GW642444(VI) Combination in Healthy Subjects and Subjects With Severe Renal Impairment

PHASE1

This study will assess the safety and pharmacokinetics of inhaled GSK573719...

Status

Completed

Location

GSK Investigational Site

Start Date

2012-03-29

Trial ID

NCT01571999

Treatments Being Tested

Inhaled GSK573719 Inhaled GSK573719/vilanterol

A Long-term Safety Study of Fluticasone Furoate (FF)/GW642444 in Japanese Subjects With COPD

PHASE3

The primary purpose of the study is to evaluate the safety and tolerability...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-08

Trial ID

NCT01192191

Treatments Being Tested

Fluticasone Furoate/GW642444 Inhalation Powder 100/25mcg Fluticasone Furoate/GW642444 Inhalation Powder 200/25mcg

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444. Study A

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-01

Trial ID

NCT01328444

Treatments Being Tested

GSK 573719 +GW642444 125/25 GSK573719 + GW642444 62.5/25 GSK 573719 125 GSK 573719 62.5 GW642444 25 Plb

A Study To Investigate The Effect Of Inhaling A Single Dose Of GW642444M In COPD Patients.

PHASE2

This study will involve the use of a new compound, GW642444 that is being d...

Status

Completed

Location

GSK Investigational Site

Start Date

2007-08

Trial ID

NCT00519376

Treatments Being Tested

GW642444M GW642444H placebo

An Exercise Endurance Study to Evaluate the Effects of Treatment of Chronic Obstructive Pulmonary Disease (COPD) Patients With a Dual Bronchodilator: GSK573719/GW642444.Study B

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-16

Trial ID

NCT01323660

Treatments Being Tested

GSK573719/GW642444 125/25 GSK573719/GW642444 62.5/25 GSK573719 125 GSK573719 62.5 GW642444 25 placebo

A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPD

PHASE3

This is a phase III multicenter, randomized, double-blind, placebo-controll...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-01

Trial ID

NCT01313650

Treatments Being Tested

62.5/25mcg 62.5mcg 25mcg Placebo

A 52-Week, Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Evaluate the Safety and Tolerability of GSK573719/GW642444 and GSK573719 in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The purpose of this 52-week study is to evaluate the long-term safety (in t...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-01-01

Trial ID

NCT01316887

Treatments Being Tested

125/25 mcg once-daily GSK573719/GW642444 125mcg once-daily GSK573719 Placebo once-daily

A Drug Interaction Study With Fluticasone Furoate/GW642444 Inhalation Powder and Ketoconazole

PHASE1

A randomized two-way crossover study to determine whether concomitant admin...

Status

Completed

Location

GSK Investigational Site

Start Date

2010-07-01

Trial ID

NCT01165125

Treatments Being Tested

FF / GW642444 ketoconazole ketoconazole (placebo to match)

Study Evaluating the 24-Hour Pulmonary Function Profile of Fluticasone Furoate (FF) /GW642444 (Vilanterol) (VI) Inhalation Powder 100/25mcg Once Daily Compared With Fluticasone Propionate/Salmeterol Inhalation Powder 250/50mcg Twice Daily in Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE3

The purpose of this study is to evaluate the 24-hour spirometry effect (FEV...

Status

Completed

Location

GSK Investigational Site

Start Date

2011-03-18

Trial ID

NCT01323621

Treatments Being Tested

Fluticasone Furoate 100mcg/ GW642444 (vilanterol) 25mcg Fluticasone Propionate 250mcg / salmeterol 50mcg Double-dummy placebo Salbutamol as needed

A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)

PHASE2

This study will assess the safety and efficacy of 5 doses GW642444 in subje...

Status

Completed

Location

GSK Investigational Site

Start Date

2008-02

Trial ID

NCT00606684

Treatments Being Tested

GW642444 6.25 GW642444 3mcg GW642444 12.5mcg GW642444 25mcg GW642444 50mcg placebo

Previous Next